<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03112980</url>
  </required_header>
  <id_info>
    <org_study_id>DEDICATE</org_study_id>
    <secondary_id>DEDICATE - DZHK 6</secondary_id>
    <nct_id>NCT03112980</nct_id>
  </id_info>
  <brief_title>Randomized Trial of TAVI vs. SAVR in Patients With Severe Aortic Valve Stenosis at Intermediate Risk of Mortality</brief_title>
  <acronym>DEDICATE</acronym>
  <official_title>Randomized, Multi-Center, Event-Driven Trial of TAVI Versus SAVR in Patients With Symptomatic Severe Aortic Valve Stenosis and Intermediate Risk of Mortality, as Assessed by STS-Score - DEDICATE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Deutsche Herzstiftung e.V.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized controlled, multi-center trial randomizing patients with symptomatic severe aortic&#xD;
      stenosis at low to intermediate operative risk of mortality in a 1:1 fashion to transcatheter&#xD;
      aortic valve implantation (TAVI) or surgical aortic valve replacement (SAVR) to test, whether&#xD;
      TAVI is non-inferior to SAVR, as measured by all-cause mortality or stroke after 1 and 5&#xD;
      years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A paradigm-shift towards performing TAVI in intermediate- and low-risk patients has already&#xD;
      begun, as procedural results of TAVI have improved significantly within the past years.&#xD;
      Nevertheless, a prospective and independent comparison of surgical (SAVR) and interventional&#xD;
      (TAVI) valve therapy in patients considered at low to intermediate risk that covers an&#xD;
      &quot;all-comers&quot; patient population and multiple devices has not yet been performed.&#xD;
&#xD;
      The DEDICATE-trial is designed as a prospectively randomized (1:1), multi-center,&#xD;
      comparator-controlled interventional trial to investigate whether transcatheter aortic valve&#xD;
      implantation (TAVI) is non-inferior - as measured by all-cause mortality or stroke after 1&#xD;
      and 5 years - compared to surgical aortic valve replacement (SAVR) in the treatment of&#xD;
      patients with symptomatic severe aortic stenosis at low to intermediate operative risk of&#xD;
      mortality, as assessed by the local Heart Team.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 10, 2017</start_date>
  <completion_date type="Anticipated">March 2027</completion_date>
  <primary_completion_date type="Anticipated">March 2027</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from stroke or death</measure>
    <time_frame>within 5 years after randomization</time_frame>
    <description>(Efficacy endpoint)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom from stroke or death</measure>
    <time_frame>within 1 year after randomization</time_frame>
    <description>(Safety endpoint)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Freedom from stroke or death</measure>
    <time_frame>Five years after last patient in</time_frame>
    <description>will be assessed at every study visit and compared between TAVI and SAVR groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Five years after last patient in</time_frame>
    <description>will be assessed at every study visit and compared between TAVI and SAVR groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from cardiovascular mortality</measure>
    <time_frame>Five years after last patient in</time_frame>
    <description>will be assessed at every study visit and compared between TAVI and SAVR groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from the composite of all-cause mortality and stroke</measure>
    <time_frame>Five years after last patient in</time_frame>
    <description>will be assessed at every study visit and compared between TAVI and SAVR groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from myocardial infarction</measure>
    <time_frame>Five years after last patient in</time_frame>
    <description>will be assessed at every study visit and compared between TAVI and SAVR groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from stroke</measure>
    <time_frame>Five years after last patient in</time_frame>
    <description>will be assessed at every study visit and compared between TAVI and SAVR groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from major or life-threatening / disabling bleeding</measure>
    <time_frame>Five years after last patient in</time_frame>
    <description>will be assessed at every study visit and compared between TAVI and SAVR groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from acute kidney injury</measure>
    <time_frame>Five years after last patient in</time_frame>
    <description>will be assessed at every study visit and compared between TAVI and SAVR groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from vascular access site and access-related complications</measure>
    <time_frame>Five years after last patient in</time_frame>
    <description>will be assessed at every study visit and compared between TAVI and SAVR groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from conduction disturbances and arrhythmias, need for permanent pacemaker implantation</measure>
    <time_frame>Five years after last patient in</time_frame>
    <description>will be assessed at every study visit and compared between TAVI and SAVR groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from residual aortic regurgitation ≥ moderate</measure>
    <time_frame>Five years after last patient in</time_frame>
    <description>will be assessed at every study visit and compared between TAVI and SAVR groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite device success</measure>
    <time_frame>Five years after last patient in</time_frame>
    <description>Number of participants with freedom from procedural mortality and correct positioning of a single transcatheter heart valve (THV) in the proper position with intended performance (no prosthesis- patient mismatch and mean aortic valve gradient &lt;20 mmHg or peak velocity &lt;3 m/s, AND no moderate or severe prosthetic valve regurgitation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite early safety</measure>
    <time_frame>within first 30 days after procedure</time_frame>
    <description>Number of participants dying and/or number of participants with stroke (disabling and non-disabling), and/or life-threatening bleeding and/or acute kidney injury stages 2/3 and/or coronary artery obstruction requiring Intervention and/or major vascular complication and/or valve-related dysfunction requiring repeat procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite clinical efficacy</measure>
    <time_frame>within first 30 days after procedure</time_frame>
    <description>Number or participants dying and/or number of participants with stroke (disabling and non-disabling) and/or rehospitalisation for worsening heart failure or valve-related symptoms and/or New York Heart Association functional class (NYHA) III or IV and/or valve-related dysfunction (mean aortic valve gradient &gt;20 mmHg, effective orifice area (EOA) &lt;0.9-1.1 cm2 and/or Doppler Velocity Index (DVI) &lt;0. 35 m/s, AND/OR moderate or severe prosthetic valve regurgitation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from prosthetic valve dysfunction</measure>
    <time_frame>Five years after last patient in</time_frame>
    <description>will be assessed at every study visit and compared between TAVI and SAVR groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from prosthetic aortic valve endocarditis</measure>
    <time_frame>Five years after last patient in</time_frame>
    <description>will be assessed at every study visit and compared between TAVI and SAVR groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from the composite time-related valve safety</measure>
    <time_frame>Five years after last patient in</time_frame>
    <description>Number of participants with structural valve deterioration (including repeat procedures, prosthetic valve endocarditis and/or thrombosis) and/or number of participants with thromboembolic events (stroke) and/or Valve Academic Research Consortium (VARC-2) bleeding (unless clearly unrelated to valve therapy).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life measures</measure>
    <time_frame>Five years after last patient in</time_frame>
    <description>Number of participants with reduced quality of life measures after valve replacement as compared to baseline levels prior to valve-replacement, assessed using EuroQol five dimensions (EQ-5D) questionnaire and/or Barthel Index and/or center for epidemiologic studies depression (CES-D) Scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economic analysis</measure>
    <time_frame>Five years after last patient in</time_frame>
    <description>Incremental cost-effectiveness of TAVI compared to surgical valve replacement, by using quality adjusted life years (QALYs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of (re) hospitalisations</measure>
    <time_frame>Five years after last patient in</time_frame>
    <description>Number rehospitalisations of all participants. Length of stay in hospital</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1404</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>Transcatheter aortic valve implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transcatheter aortic valve implantation (TAVI) using the most appropriate CE (Conformité Européene)-marked device available, with a minimum demand of experience of 30 implanted devices/type per center.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgical aortic valve replacement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Surgical aortic valve replacement (SAVR) with free choice of surgical bioprosthesis and free choice of surgical access according to the surgeon's preference.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcatheter aortic valve implantation</intervention_name>
    <description>(TAVI)</description>
    <arm_group_label>Transcatheter aortic valve implantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical aortic valve replacement</intervention_name>
    <description>(SAVR)</description>
    <arm_group_label>Surgical aortic valve replacement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Heart team consensus that TAVI and SAVR are both medically justified and advisable&#xD;
             based on:&#xD;
&#xD;
               1. Degenerative aortic valve stenosis with echocardiographically derived criteria:&#xD;
&#xD;
                    -  Mean gradient &gt;40 mmHg or&#xD;
&#xD;
                    -  Jet velocity greater than 4.0 m/s or&#xD;
&#xD;
                    -  Aortic valve area (AVA) of &lt; 1.0 cm2 (indexed effective orifice area &lt;&#xD;
                       0.6cm2/m2).&#xD;
&#xD;
               2. Patient is symptomatic from his/her aortic valve stenosis&#xD;
&#xD;
                    -  New York Heart Association Functional Class ≥ II or&#xD;
&#xD;
                    -  Angina pectoris or&#xD;
&#xD;
                    -  Syncope.&#xD;
&#xD;
               3. Patient is classified as low to intermediate operative risk as assessed by the&#xD;
                  local heart team according to the variables outlined in the 2017 ESC/EACTS&#xD;
                  Guidelines for the Management of valvular heart disease, taking into account&#xD;
                  cardiac and extracardiac Patient characteristics and established risk scores&#xD;
                  (e.g. STS-PROM, EuroSCORE).&#xD;
&#xD;
               4. A transfemoral or alternative (e.g. transapical, transaortic, transaxillary)&#xD;
                  access for TAVI seems feasible. Centers should follow a &quot;transfemoral first&quot;&#xD;
                  strategy for the primary route of access; however, other routes of access are&#xD;
                  also allowed, as decided by local heart team consensus.&#xD;
&#xD;
          2. Patient has provided written informed consent to participate in the trial.&#xD;
&#xD;
          3. Ability of the patient to understand the patient information and to personally sign&#xD;
             and date the informed consent to participate in the study, before performing any study&#xD;
             related procedures.&#xD;
&#xD;
          4. The patient agrees to undergo SAVR, if randomized to control treatment.&#xD;
&#xD;
          5. The patient and the treating physician agree that the patient will return for all&#xD;
             required post-procedure follow-up visits.&#xD;
&#xD;
          6. Patients aged 65 to 85 years.&#xD;
&#xD;
          7. Male patients or females who are postmenopausal defined as no menses for 12 months&#xD;
             without an alternative medical cause.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Aortic valve is a congenital unicuspid or congenital bicuspid valve, or is&#xD;
             non-calcified&#xD;
&#xD;
          2. Untreated clinically significant coronary artery disease considered a contraindication&#xD;
             to an isolated aortic valve procedure (TAVI or SAVR) according to heart team consensus&#xD;
&#xD;
          3. Previous cardiac surgery&#xD;
&#xD;
          4. Any percutaneous coronary intervention performed within 1 month prior to the study&#xD;
             procedure&#xD;
&#xD;
          5. Untreated severe mitral or tricuspid regurgitation&#xD;
&#xD;
          6. Untreated severe mitral stenosis&#xD;
&#xD;
          7. Hemodynamic instability requiring inotropic support or mechanical circulatory support&#xD;
&#xD;
          8. Ischemic stroke or intracranial bleeding within 1 month&#xD;
&#xD;
          9. Severe ventricular dysfunction with left ventricular ejection fraction &lt; 20% as&#xD;
             measured by resting echocardiogram&#xD;
&#xD;
         10. Hypertrophic obstructive cardiomyopathy or severe basal septal hypertrophy with&#xD;
             outflow gradient&#xD;
&#xD;
         11. Echocardiographic evidence of an intracardiac mass, thrombus, vegetation or&#xD;
             endocarditis&#xD;
&#xD;
         12. Any other condition considered a contraindication for an isolated aortic valve&#xD;
             procedure&#xD;
&#xD;
         13. Symptomatic carotid or vertebral artery disease&#xD;
&#xD;
         14. Expected life expectancy &lt; 12 months due to associated non-cardiac comorbidities&#xD;
&#xD;
         15. Currently participating in another investigational drug or device trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Blankenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitäres Herz- und Gefäßzentrum Hamburg (UHZ), Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jochen Cremer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Schleswig-Holstein, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Moritz Seiffert, MD</last_name>
    <phone>+49 (0) 40 7410 58206</phone>
    <email>m.seiffert@uke.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefan Blankenberg, MD</last_name>
    <phone>+49 (0) 40 7410 53972</phone>
    <email>s.blankenberg@uke.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Uniklinik Rheinisch-Westfälische Technische Hochschule Aachen</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zakiya Coenen-Basmadjie</last_name>
      <email>zcoenen@ukaachen.de</email>
    </contact>
    <investigator>
      <last_name>Jörg Schröder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rüdiger Autschbach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitäts-Herzzentrum Freiburg-Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriele Lechner</last_name>
      <email>gabriele.lechner@universitaets-herzzentrum.de</email>
    </contact>
    <investigator>
      <last_name>Franz Josef Neumann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Holger Schröfel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kerckhoff-Klinik Bad Nauheim</name>
      <address>
        <city>Bad Nauheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A. Kirchhof</last_name>
      <email>a.kirchhof@kerckhoff-fgi.de</email>
    </contact>
    <investigator>
      <last_name>Won-Keun Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yeong-Hoon Choi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herz- und Gefässklinik Bad Neustadt/Saale</name>
      <address>
        <city>Bad Neustadt an der Saale</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Back</last_name>
      <email>monika.back@herzchirurgie.de</email>
    </contact>
    <investigator>
      <last_name>Anno Diegeler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sebastian Kerber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herz- und Diabeteszentrum NRW Bad Oeynhausen</name>
      <address>
        <city>Bad Oeynhausen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minko Nnanga</last_name>
      <email>hminko-nnanga@hdz-nrw.de</email>
    </contact>
    <investigator>
      <last_name>René Schramm, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Volker Rudolph, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin (Campus Benjamin-Franklin)</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katja Hubert</last_name>
      <email>katja.hubert@charite.de</email>
    </contact>
    <investigator>
      <last_name>Ulf Landmesser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Volkmar Falk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin (Campus Mitte)</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin (Campus Virchow)</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bianca Papke</last_name>
      <email>bianca.papke@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Sophia Strempel</last_name>
      <email>sophia.strempel@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Mohammad Sherif, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Volkmar Falk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Post</last_name>
      <email>post@dhzb.de</email>
    </contact>
    <investigator>
      <last_name>Volkmar Falk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Burkert Pieske, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vivantes Friedrichshain</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mediha San</last_name>
      <email>mediha.san@vivantes.de</email>
    </contact>
    <investigator>
      <last_name>Stephan Kische, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Volkmar Falk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vivantes Humboldt Kliniken</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum am Urban</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mediha San</last_name>
      <email>Mediha.San@vivantes.de</email>
    </contact>
    <investigator>
      <last_name>Stephan Kische, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Volkmar Falk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vivantes Neukölln</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Astrid Maselli</last_name>
      <email>astrid.maselli@vivantes.de</email>
    </contact>
    <investigator>
      <last_name>Harald Darius, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Volkmar Falk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Immanuel Klinikum Bernau</name>
      <address>
        <city>Bernau</city>
        <zip>16321</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katja Peukert</last_name>
      <email>katja.peuckert@immanuelalbertinen.de</email>
    </contact>
    <investigator>
      <last_name>Christian Butter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johannes Albes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kliniken der Ruhr-Universität Bochum</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bärbel Buchwald</last_name>
      <email>baerbel.buchwald@bergmannsheil.de</email>
    </contact>
    <investigator>
      <last_name>Andreas Mügge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Justus Strauch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Brandenburg Theodor Fontane</name>
      <address>
        <city>Brandenburg an der Havel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uta Hiller</last_name>
      <email>u.hiller@klinikum-brandenburg.de</email>
    </contact>
    <investigator>
      <last_name>Oliver Ritter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Dresden an der Technischen Universität Dresden</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marion Mai</last_name>
      <email>marion.mai@tu-dresden.de</email>
    </contact>
    <investigator>
      <last_name>Axel Linke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rabea Wagstaff</last_name>
      <email>Rabea.Wagstaff@med.uni-duesseldorf.de</email>
    </contact>
    <investigator>
      <last_name>Tobias Zeus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Artur Lichtenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sigrun Fechner</last_name>
      <email>sigrun.fechner@uk-erlangen.de</email>
    </contact>
    <investigator>
      <last_name>Stefan Achenbach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Weyand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen, Klinikum für Kardiologie und Angiologie am Westdeutschen Herz- und Gefäßzentrum</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Dumin</last_name>
      <email>martin.dumin@uk-essen.de</email>
    </contact>
    <investigator>
      <last_name>Tienush Rassaf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arjang Ruhparwar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vera Jakobi</last_name>
      <email>vera.jakobi@kgu.de</email>
    </contact>
    <investigator>
      <last_name>Mariuca Vasa-Nicotera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Walther, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitäts-Herzzentrum Freiburg-Bad Krozingen</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Trabitzsch</last_name>
      <email>barbara.trabitzsch@uniklinik-freiburg.de</email>
    </contact>
    <investigator>
      <last_name>Constantin von zur Mühlen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wolfgang Bothe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Giessen und Marburg</name>
      <address>
        <city>Giessen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ursula Böning</last_name>
      <email>ursula.boening@innere.med.uni-giessen.de</email>
    </contact>
    <investigator>
      <last_name>Holger Nef, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Roth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Greifswald / Klinikum Karlsburg</name>
      <address>
        <city>Greifswald / Karlsburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petra Paschen</last_name>
      <email>p.paschen@drguth.de</email>
    </contact>
    <investigator>
      <last_name>Stephan Felix, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexander Kaminsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Göttingen</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessika Jordan</last_name>
      <email>jessika.jordan@med.uni-goettingen.de</email>
    </contact>
    <investigator>
      <last_name>Hassina Baraki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tim Seidler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle (Saale)</name>
      <address>
        <city>Halle (Saale)</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathrin Ludwig</last_name>
      <email>kathrin.ludwig@uk-halle.de</email>
    </contact>
    <investigator>
      <last_name>Daniel Sedding, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Britt Hofmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitäres Herz- und Gefäßzentrum Hamburg (UHZ)</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moritz Seiffert, MD</last_name>
      <phone>+49 (0) 40 7410 58206</phone>
      <email>m.seiffert@uke.de</email>
    </contact>
    <investigator>
      <last_name>Stefan Blankenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lenard Conradi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annette Hoffmann-Koch</last_name>
      <email>Hoffmann-Koch.Annette@mh-hannover.de</email>
    </contact>
    <investigator>
      <last_name>Serghei Cebotari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johann Bauersachs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal Syren</last_name>
      <email>Pascal.Syren@med.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Gregor Warnecke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florian Leuschner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sissy Grund</last_name>
      <email>Sissy.Grund@med.uni-jena.de</email>
    </contact>
    <investigator>
      <last_name>Christian Schulze, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Torsten Doenst, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doreen Brehm</last_name>
      <email>doreen.brehm@uksh.de</email>
    </contact>
    <contact_backup>
      <last_name>Petra Röthgen</last_name>
      <email>petra.roethgen@uksh.de</email>
    </contact_backup>
    <investigator>
      <last_name>Derk Frank, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jochen Cremer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bundeswehrzentralkrankenhaus Koblenz</name>
      <address>
        <city>Koblenz</city>
        <zip>56076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sascha Lengler, MD</last_name>
      <email>saschalengler@bundeswehr.org</email>
    </contact>
    <investigator>
      <last_name>Jörg Jöckel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christoph Bickel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Lenz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herzzentrum der Uniklinik Köln</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vera Wolf</last_name>
      <email>vera.wolf@uk-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Elmar Kuhn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephan Baldus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Kathrin Funkat</last_name>
      <email>anne-kathrin.funkat@leipzig-heart.de</email>
    </contact>
    <investigator>
      <last_name>Holger Thiele, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Holzhey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitäres Herzzentrum Lübeck</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roza Meyer-Saraei</last_name>
      <email>Roza.Meyer-Saraei@uksh.de</email>
    </contact>
    <investigator>
      <last_name>Stephan Ensminger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ingo Eitel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Otto-von Guericke-Universität Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esther Meyer</last_name>
      <email>esther.meyer@med.ovgu.de</email>
    </contact>
    <investigator>
      <last_name>Rüdiger Braun-Dullaeus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maximilian Scherner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lea Frohnweiler</last_name>
      <email>lea.frohnweiler@unimedizin-mainz.de</email>
    </contact>
    <investigator>
      <last_name>Stephan von Bardeleben, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel-Sebastian Dohle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum München</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Simon</last_name>
      <email>simons@dhm.mhn.de</email>
    </contact>
    <investigator>
      <last_name>Stephanie Voss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Joner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LMU Klinikum der Universität München</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janina Neubarth-Meyer</last_name>
      <email>janina.neubarth@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Christian Hagl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steffen Massberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antje Hellige</last_name>
      <email>antje.hellige@ukmuenster.de</email>
    </contact>
    <investigator>
      <last_name>Helmut Baumgartner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sven Martens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Büsing</last_name>
      <email>Monika.Buesing@ukr.de</email>
    </contact>
    <investigator>
      <last_name>Lars Maier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christof Schmid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Robert Bosch Krankenhaus</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanne Grünsfelder</last_name>
      <email>susanne.gruensfelder@rbk.de</email>
    </contact>
    <investigator>
      <last_name>Raffi Bekeredjian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ulrich Franke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uta Dichristin</last_name>
      <email>uta.dichristin@uniklinik-ulm.de</email>
    </contact>
    <investigator>
      <last_name>Wolfgang Rottbauer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andreas Liebold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 21, 2017</study_first_submitted>
  <study_first_submitted_qc>April 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2017</study_first_posted>
  <last_update_submitted>September 5, 2021</last_update_submitted>
  <last_update_submitted_qc>September 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aortic Valve Stenosis</keyword>
  <keyword>Transcatheter Aortic Valve Replacement</keyword>
  <keyword>Surgical aortic valve replacement</keyword>
  <keyword>Low to intermediate operative risk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

